Last Updated on 2026 年 3 月 18 日 by 総合編集組
Global Dry Eye Disease Treatment Landscape in 2026: Market Growth, Reproxalap Challenges, and Emerging Innovations
Introduction to Dry Eye Disease Burden Dry Eye Disease (DED) has evolved from a simple ocular discomfort into a multifaceted chronic condition involving tear film instability, ocular surface inflammation, and neurosensory abnormalities. Classified into aqueous-deficient, evaporative (most common, over 75% of cases linked to Meibomian Gland Dysfunction or MGD), and mixed types, DED prevalence surges due to aging populations, prolonged screen exposure, environmental pollution, and air conditioning use. The global dry eye syndrome treatment market reached USD 6.29 billion in 2024 and is projected to expand to USD 9.20 billion by 2030, maintaining a steady CAGR of 6.5%. In the U.S., affected individuals range from 16 million to 49 million, fueling intensive pharmaceutical R&D for faster-onset, lower-side-effect therapies.
Innovative Mechanism: Aldeyra Therapeutics and Reproxalap Aldeyra Therapeutics (ALDX) focuses on immune-mediated diseases by modulating protein systems rather than single-target inhibition, aiming for broad inflammation control with reduced toxicity. Their lead candidate, Reproxalap, is a first-in-class small-molecule Reactive Aldehyde Species (RASP) modulator. RASPs, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), accumulate under oxidative stress in DED patients’ tears, correlating with disease severity. These aldehydes covalently bind to thiols and amines in proteins, DNA, and lipids, activating pathways like NF-κB, MAPK, and NLRP3 inflammasome, releasing pro-inflammatory cytokines (IL-1β, IL-18) and matrix metalloproteinases (MMPs), damaging corneal epithelium and inducing apoptosis. Reproxalap neutralizes RASPs upstream, potentially outperforming traditional NSAIDs, corticosteroids, or late-stage immunomodulators.
Clinical Data Overview Over 2,500 patients participated in Reproxalap trials, demonstrating rapid onset. In Phase 2a, the 0.1% concentration improved symptoms within one week, with significant gains in SANDE scores (symptoms), ODS (ocular discomfort), Schirmer tear volume, and Lissamine Green conjunctival staining (P values supportive in early data). Adverse events were mostly mild, transient instillation-site stinging.
Regulatory Hurdles (2023–2026) Despite promising signs, FDA approval proved arduous. The first Complete Response Letter (CRL) arrived in November 2023, citing insufficient efficacy evidence for symptoms despite no safety or manufacturing issues. Aldeyra resubmitted in June 2025, targeting a PDUFA date of December 16, 2025. In December 2025, FDA requested a full Clinical Study Report (CSR) for the Field Trial (despite its primary endpoint missing significance), extending PDUFA to March 16, 2026.
On March 17, 2026, Aldeyra received a third CRL, stating lack of substantial evidence from adequate, well-controlled studies; inconsistent results raising reliability concerns; and overall data failing to support efficacy under proposed labeling. No safety concerns noted. Aldeyra plans a Type A meeting to clarify required actions but currently has no plans for additional large trials.
Strategic Partnership with AbbVie In October 2023, Aldeyra signed an option agreement with AbbVie: USD 6 million upfront for U.S. co-development/commercialization rights and ex-U.S. exclusive license. Upon exercise (within 10 business days post-approval), AbbVie pays USD 100 million upfront, another USD 100 million on approval, up to USD 300 million total milestones, with 60/40 (AbbVie/Aldeyra) cost/profit sharing in the U.S. The third CRL delays realization, posing significant risk to this high-value alliance.
Current Prescription Drug Landscape and Competition The market shifts from lubricants to mechanism-based therapies:
- Restasis (cyclosporine 0.05% emulsion): 2003 approval, T-cell inhibitor boosting natural tears; slow onset (3–6 months), burning common; generics available post-2022.
- Xiidra (lifitegrast 5%): 2016, LFA-1 antagonist blocking inflammation adhesion; faster (some in 2 weeks), but dysgeusia frequent.
- Cequa (cyclosporine 0.09% nanomicellar): Enhanced penetration, better tear production.
- Miebo (perfluorohexyloctane): 2023, first evaporative DED-targeted non-aqueous drop; forms protective layer mimicking lipids, rapid relief.
- Vevye (cyclosporine 0.1% semifluorinated alkane): Water-free, improved bioavailability; significant corneal staining reduction in 4 weeks.
- Tyrvaya (varenicline nasal spray): Neural stimulation via trigeminal pathway; induces full tear film secretion in minutes; sneezing/throat irritation possible.
- Tryptyr (acoltremon 0.003%): 2025 approval, TRPM8 agonist mimicking cooling to trigger reflex tearing; notable Schirmer improvement by day 14 in COMET-2/3 studies.
2025–2026 Pipeline Highlights Unmet needs persist in MGD root cause, corneal nerve repair, and sustained delivery:
- AZR-MD-001 (0.5% selenium disulfide ointment): Multi-action on MGD; Phase 2b showed increased open glands after 3 months (P=0.0004); Phase 3 ASTRO long-term safety due Q1 2026.
- RGN-259 (Thymosin β4): Preservative-free for epithelial regeneration; strong in neurotrophic keratopathy (60% complete healing in 4 weeks, SEER-1); SEER-2/3 ongoing.
- Tanfanercept (HL036): Topical TNF inhibitor fragment; VELOS-3 missed primary but strong Schirmer (P<0.001); higher dose exploration.
- AR-15512: Alcon TRPM8 agonist in Phase 3 for rapid symptom relief.
- PL9643: Melanocortin agonist; MELODY-1 Phase 3 showed superior ocular pain reduction.
Delivery Revolution Traditional drops face compliance and retention issues. Advances include:
- Biodegradable ocular implants and drug-eluting punctal plugs: Shift to quarterly maintenance (global ocular implant market ~USD 15.72 billion in 2024).
- Nanoemulsions/micelles (used in Cequa/Vevye) and smart hydrogels (chitosan/hyaluronic acid-based, pH/temperature-responsive).
- 3D-printed drug-eluting contact lenses (e.g., MediPrint LL-BMT1): Vision correction + sustained release; trials ongoing, potential post-2026 for severe cases.
Market Trends and Strategic Insights Precision diagnostics (tear osmolarity, MMP-9) guide prescription shifts from OTC. Average daily screen time reached 7 hours in 2025, driving preservative-free single-dose demand. Patent expiries (e.g., Restasis) push upgrades (emulsion to anhydrous). True “disease-modifying” mechanisms (RASP modulation, nerve regeneration, MGD targeting) command premium pricing.
Conclusion: Future Outlook Reproxalap’s innovative RASP approach remains conceptually promising despite 2026 setbacks, highlighting placebo vehicle effects in DED trials. The field diversifies: targeted anti-inflammation, anhydrous stabilization, physical MGD repair, and neural stimulation. Over the next 3–5 years, “drug-device combos” and regenerative therapies may reshape chronic DED management.
